Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 0.70 |
| ▸ | HSD11B2 | P80365 | 10/20 | 0.70 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6529966 | 0.92 | HSD11B1 (0.61) | HSD11B1HSD11B2GRM1 | |
| SCHEMBL233203 | 0.91 | HSD11B1 (0.71) | HSD11B1HSD11B2 | |
| SCHEMBL231962 | 0.88 | HSD11B1 (0.72) | HSD11B1HSD11B2GRM1 | |
| SCHEMBL231137 | 0.85 | HSD11B1 (0.66) | HSD11B1HSD11B2GRM1 | |
| SCHEMBL232663 | 0.84 | HSD11B1 (0.78) | HSD11B1HSD11B2 | |
| SCHEMBL233071 | 0.83 | HSD11B1 (0.66) | HSD11B1HSD11B2 | |
| SCHEMBL231839 | 0.83 | HSD11B1 (1.00) | HSD11B1HSD11B2 | |
| SCHEMBL233136 | 0.82 | HSD11B1 (0.65) | HSD11B1HSD11B2 | |
| SCHEMBL235093 | 0.82 | HSD11B1 (0.74) | HSD11B1HSD11B2 | |
| SCHEMBL232579 | 0.82 | HSD11B1 (0.62) | HSD11B1HSD11B2GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133145-B2 | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-1751108-B1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130338169-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8415354-B2 | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2013-04-09 | — | — | US | disclosed |
| US-8372841-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120004206-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. | 2012-01-05 | — | — | US | disclosed |
| EP-2345640-A1 | Adamantyl- acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7880001-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100222316-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2010-09-02 | — | — | US | disclosed |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-30 | — | — | US | disclosed |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222316-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885GRM1 682/4885 |
| US-20130338169-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885GRM1 620/4885 |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885GRM1 620/4885 |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885GRM1 682/4885 |
| US-20120004206-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885GRM1 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.